Heparin and its derivatives - Present and future

References
1 Harenberg J, Casu B. Semin Thromb Haemost. 2007. 33 449-561.
2 Harenberg J, Casu B. Semin Thromb Haemost. 2002. 28 323-402.
3 Harenberg J, Casu B. Semin Thromb Haemost. 1994. 20 135-225.
4 Harenberg J, Casu B. Nonanticoagulant Actions of Glycosaminoglycans. Plenum Press; New York: 1996: 1-286.
5 Petitou M, Nancy-Portebois V, Dubreucq G. et al. From heparin to EP217609: The long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 2009; 102: 804-810.
6 Harenberg J. Development of Idraparinux and Idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009; 102: 811-815.
7 Schlesinger M, Simonis D, Schmitz P. et al. Binding between heparin and the integrin VLA-4. Thromb Haemost 2009; 102: 816-822.
8 Li J-P, Vlodabky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 2009; 102: 823-828.
9 Fonseca RJC, Santos GRC, Maurão PAS. Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding: Practical and conceptual implications. Thromb Haemost 2009; 102: 829-836.
10 Collino M, Castiglia S, Manoni M. et al. Effects of a semi-synthetic N-,O-sulfated glycosaminoglycan K5 polysaccharide derivative in a rat model of cerebral ischemia/reperfusion injury. Thromb Haemost 2009; 102: 837-845.
11 Liverani L, Mascellani G, Spelta F. Heparins: Process-related physico-chemical and compositional characteristics, fingerprints and impurities. Thromb Haemost 2009; 102: 846-853.
12 Sasisekharan R, Shriver Z. From crisis to opportunity: A Perspective on the Heparin Crisis. Thromb Haemost 2009; 102: 854-858.
13 Guerrini M, Shriver Z, Bisio A. et al. The tainted heparin story: An update. Thromb Haemost 2009; 102: 907-911.
14 Szelke H, Harenberg J, Krämer R. Detection and neutralisation of heparin by a fluorescent ruthenium compound. Thromb Haemost 2009; 102: 859-864.
15 Vismara E, Pierini M, Mascellani G. et al. Low molecular weight heparin from Cu2+ and Fe2+ Fenton type depolymerisation processes. Thromb Haemost. 2009 in press..
16 Bisio A, Vecchietti D, Cittrerio L. et al. Structural features of low molecular weight heparins affecting their affinity to antithrombin. Thromb Haemost 2009; 102: 865-873.
17 Rudd TR, Skidmore MA, Guimond SE. et al. The potential for circular dichroism as an additional facile and sensitive method of monitoring low molecular weight heparins and heparinoids. Thromb Haemost 2009; 102: 874-878.
18 Vardi M, Laor A, Bitterman H. Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes. Thromb Haemost 2009; 102: 879-886.
19 Nowak G. Heparin induced thrombocytopenia (HIT II) - a drug associated autoimmune disease. Thromb Haemost 2009; 102: 887-891.
20 Laux V, Perzborn E, Heitmeier S. et al. Direct inhibitors of coagulation proteins - the end of the heparin and low molecular weight heparin era for anticoagulant therapy?. Thromb Haemost 2009; 102: 892-899.
21 Kishimoto TK, Qi YW, Long A. et al. M118 - A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes. Thromb Haemost 2009; 102: 900-906.